By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Synopsys Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Synopsys, Inc. – SNPS
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Technology > Synopsys Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Synopsys, Inc. – SNPS
Synopsys Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of 0,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Synopsys, Inc. – SNPS
Technology

Synopsys Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Synopsys, Inc. – SNPS

GlobeNews Wire
Last updated: 18/12/2025 10:38 PM
GlobeNews Wire
Published: 18/12/2025
Share
SHARE

NEW ORLEANS, Dec. 18, 2025 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 30, 2025 to file lead plaintiff applications in securities class action lawsuits against Synopsys, Inc. (“Synopsys” or the “Company”) (NasdaqGS: SNPS), if they purchased or otherwise acquired the Company’s securities between December 4, 2024 and September 9, 2025, inclusive (the “Class Period”) and/or purchased or otherwise acquired Synopsys common stock in exchange for their shares of Ansys, Inc. (“Ansys”) common stock in the acquisition of Ansys. These actions are pending in the United States District Court for the Northern District of California.

Get Help

Synopsys investors should visit us at https://www.claimsfiler.com/cases/nasdaq-snps-2 or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Synopsys and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On September 9, 2025, post-market, the Company announced its 3Q2025 financial results, disclosing quarterly revenue of $1.740 billion, missing its prior guidance of between $1.755 billion and $1.785 billion, and reported net income of $242.5 million, a 43% year-over-year decline from $425.9 million reported for 3Q 024. Further, the Company reported that its Design IP segment accounted for approximately 25% of revenue and came in at $426.6 million, a 7.7% decline year-over-year, and also provided guidance inferring that Design IP revenues will decline by at least 5% on a full-year basis in fiscal 2025.

On this news, the price of Synopsys’ shares fell $216.59, or 35.8%, to close at $387.78 per share on September 10, 2025, on unusually heavy trading volume.

The first-filed case is Kim v. Synopsis, Inc., et al., No. 25-cv-09410. A subsequent case, New England Teamsters Pension Fund v. Synopsis, Inc., et al., No. 25-cv- 10201, expanded the class period.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

Health Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers Disease
Varvee Global Limited (VGL) Posts Strong Operational Profit & EBDITA for Q2FY26: +80% Revenue Growth, 49.8% EBITDA Margin; PAT +23.5% YoY; H1 PAT +15.7% and Attaining Near-Zero Debt
Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina
(Editorial) Innovation in Motion: The Story Behind Hyundai Motor Groups 2Stage Motor System
Manipal Hospital Sarjapur Road Launches Dedicated Deep Brain Stimulation (DBS) Clinic for Advanced Movement Disorder and Psychiatric Care
TAGGED:100,000actionAdventureagainstalert:claimsfilerclassdeadlineexcessinc.investorslawsuitsleadlossesnewsplaintiffremindsshareholdersnpssynopsyswith
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
ASK4SAM: Silberstein & Miklos, P.C. Expands Focus on Commercial Vehicle Accident Cases in Fordham, the Bronx  Truck and Bus Collisions
Technology

ASK4SAM: Silberstein & Miklos, P.C. Expands Focus on Commercial Vehicle Accident Cases in Fordham, the Bronx Truck and Bus Collisions

GlobeNews Wire
GlobeNews Wire
14/10/2025
Saudi Ministry of Finance Welcomes 2025 IMF Article IV Consultation Report
Best ACV Gummies 2026 Report: True Keto Fusion Analyzed in New Year Keto-ACV Industry Analysis
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Canfornav opens a new office in Hong Kong
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?